-
H.C. Wainwright Reiterates Buy Rating on Processa Pharmaceuticals (PCSA)
-
Processa Pharmaceuticals (PCSA) PT Lowered to $2 at H.C. Wainwright
-
Processa Pharmaceuticals Inc. (PCSA) Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
-
Processa Pharmaceuticals Inc. (PCSA) announces three abstracts for ASCO 2025
-
H.C. Wainwright Reiterates Buy Rating on Processa Pharmaceuticals (PCSA)
-
Processa Pharmaceuticals (PCSA) Provides Product Pipeline and Financial Update
-
H.C. Wainwright Reiterates Buy Rating on Processa Pharmaceuticals (PCSA)
-
Processa Pharmaceuticals Inc. (PCSA) Reports Positive Preclinical Data for NGC-Iri
-
Processa Pharmaceuticals (PCSA) PT Lowered to $6 at H.C. Wainwright
-
Processa Pharmaceuticals Inc. (PCSA) Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
-
Processa Pharmaceuticals Inc. (PCSA) Appoints Russell L. Skibsted as CFO
-
Processa Pharmaceuticals Inc. (PCSA) Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

